RHÖN-KLINIKUM Management

Management criteria checks 4/4

We currently do not have sufficient information about the CEO.

Key information

Tobias Kaltenbach

Chief executive officer

€507.0k

Total compensation

CEO salary percentage	98.6%
CEO tenure	1.4yrs
CEO ownership	n/a
Management average tenure	3.6yrs
Board average tenure	3.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Tobias Kaltenbach's remuneration changed compared to RHÖN-KLINIKUM's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	€507k	€500k	€39m
Sep 30 2023	n/a	n/a	€32m
Jun 30 2023	n/a	n/a	€26m
Mar 31 2023	n/a	n/a	€30m
Dec 31 2022	€547k	€83k	€25m

Compensation vs Market: Tobias's total compensation ($USD543.87K) is below average for companies of similar size in the Austrian market ($USD1.64M).

Compensation vs Earnings: Tobias's compensation has been consistent with company performance over the past year.

CEO

Tobias Kaltenbach (63 yo)

1.4yrs

Tenure

€507,000

Compensation

Dr. Tobias Kaltenbach is Chief Executive Officer & Chairman of the Management Board at RHÖN-KLINIKUM Aktiengesellschaft from November 2022. Mr. Kaltenbach served as Chairman of Corporate Management at Askl...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Tobias Kaltenbach	CEO & Chairman of Management Board	1.4yrs	€507.00k	no data
Stefan Stranz	CFO & Member of Management Board	3.6yrs	€543.00k	no data
Gunther Weiß	COO & Member of Management Board	5.9yrs	€625.00k	no data
Julian Schmitt	Head of Investor Relations & Treasury	no data	no data	no data
Eugen Münch	Chief Representative	3.7yrs	€219.00k	no data

3.6yrs

Average Tenure

55yo

Average Age

Experienced Management: RHK's management team is considered experienced (3.6 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Irmtraut Gurkan	Member of Supervisory Board	3.7yrs	€43.00k	no data
Georg Schulze-Ziehaus	First Deputy Chairman of the Supervisory Board	13.8yrs	€60.00k	no data
Peter Berghofer	Member of Supervisory Board	13.8yrs	€45.00k	no data
Oliver Salomon	Member of Supervisory Board	6.1yrs	€34.00k	no data
Christine Reißner	Member of Supervisory Board	8.8yrs	€33.00k	no data
Hafid Rifi	Second Deputy Chairman of the Supervisory Board	3.7yrs	€69.00k	no data
Jan Liersch	Chairman of Supervisory Board	3.8yrs	€102.00k	no data
Peter Ducke	Member of Supervisory Board	3.7yrs	€39.00k	no data
Regina Dickey	Member of Supervisory Board	3.7yrs	€45.00k	no data
Thomas Pillukat	Member of Supervisory Board	3.7yrs	€37.00k	no data
Julia Dannath-Schuh	Member of Supervisory Board	3.8yrs	€31.00k	no data
Martin Mandewirth	Member of Supervisory Board	3.7yrs	€35.00k	no data

3.8yrs

Average Tenure

Experienced Board: RHK's board of directors are considered experienced (3.8 years average tenure).

RHÖN-KLINIKUM Management

Management criteria checks 4/4

Key information

Recent management updates

RHÖN-KLINIKUM Aktiengesellschaft, Annual General Meeting, Jun 09, 2021

RHÖN-KLINIKUM Aktiengesellschaft appoints Christian Höftberger as new CEO

Recent updates

Investor sentiment improves as stock rises 19%

Full year 2023 earnings released: EPS: €0.58 (vs €0.38 in FY 2022)

Investor sentiment improves as stock rises 16%

RHÖN-KLINIKUM Aktiengesellschaft to Report Q2, 2024 Results on Aug 08, 2024

Third quarter 2023 earnings released: EPS: €0.17 (vs €0.069 in 3Q 2022)

Second quarter 2023 earnings released: EPS: €0.09 (vs €0.16 in 2Q 2022)

Upcoming dividend of €0.15 per share at 1.2% yield

Full year 2022 earnings released: EPS: €0.38 (vs €0.42 in FY 2021)

RHÖN-KLINIKUM Aktiengesellschaft to Report Fiscal Year 2022 Results on Mar 30, 2023

Second quarter 2022 earnings released: EPS: €0.16 (vs €0.10 in 2Q 2021)

First quarter 2022 earnings released: EPS: €0.01 (vs €0.017 in 1Q 2021)

Third quarter 2021 earnings released: EPS €0.10 (vs €0.09 in 3Q 2020)

Second quarter 2021 earnings released: EPS €0.10 (vs €0.003 in 2Q 2020)

First quarter 2021 earnings released: EPS €0.02 (vs €0.066 loss in 1Q 2020)

RHON-KLINIKUM AG Provides Revenue Guidance for the Year 2021

RHÖN-KLINIKUM Aktiengesellschaft to Report Q2, 2021 Results on Aug 05, 2021

RHÖN-KLINIKUM Aktiengesellschaft to Report Fiscal Year 2020 Results on Feb 25, 2021

New 90-day low: €15.12

RHÖN-KLINIKUM Aktiengesellschaft, Annual General Meeting, Jun 09, 2021

RHÖN-KLINIKUM Aktiengesellschaft to Report Q4, 2020 Final Results on Mar 25, 2021

Third quarter 2020 earnings released: EPS €0.09

RHÖN-KLINIKUM Aktiengesellschaft appoints Christian Höftberger as new CEO

Medgate Holding AG acquired remaining 51% stake in Medgate Deutschland GmbH from RHÖN-KLINIKUM Aktiengesellschaft (XTRA:RHK).

RHÃ–N-KLINIKUM Aktiengesellschaft to Report Nine Months, 2020 Results on Nov 06, 2020

New 90-day low: €15.86

New 90-day low - €17.06

Upcoming Dividend of €0.25 Per Share

New 90-day low - €17.52

Asklepios Kliniken GmbH & Co. KGaA completed the acquisition of additional 42.5% stake in RHÖN-KLINIKUM Aktiengesellschaft (XTRA:RHK) from HCM SE, B. Braun Melsungen AG, Landeskrankenhilfe V.V.A.G, Asset Management Arm and others for approximately €510 million.

Asklepios Kliniken GmbH concluded the acquisition of additional 12.4% stake in RHÖN-KLINIKUM Aktiengesellschaft (XTRA:RHK) from Eugen Münch and Ingeborg Münch.

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure